To evaluate the efficacy and safety of programmed death-1 (PD-1) inhibitor (camrelizumab) in the treatment of patients with recurrent or advanced cervical cancer and endometrial cancer.

Thirty-one patients with recurrent or advanced cervical cancer and endometrial cancer who had received PD-1 inhibitor (camrelizumab) at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) from August 2019 to July 2020 were collected. The primary end points were objective response rate (ORR) and disease control rate (DCR); the secondary end points were progression-free survival (PFS) and incidence of adverse reactions.

Among the 31 patients, 24 had cervical cancer and 7 had endometrial cancer. Four patients were treated with immune monotherapy, while 27 were treated with combination immunotherapy. The ORR was 45.16% (14/31), and the DCR was 70.97% (22/31) in all patients. The follow-up time was 2.9 to 14.6 months, and the median PFS was not reached. The incidence of adverse reactions was 58.06% (18/31). The main adverse reactions were myelosuppression, reactive cutaneous capillary endothelial proliferation and thyroid dysfunction, and no adverse reactions of grade ≥ 3 in combination immunotherapy were observed.

The PD-1 inhibitor camrelizumab has certain efficacy and safety in the treatment of patients with recurrent or advanced cervical cancer and endometrial cancer.